TARA Nucleic Acid Detection Without Enzymatic Amplification

The patent extracts and eliminates the need for enzymatic amplification steps (PCR) and extensive sample preparation from the detection system. By using direct hybridization of probes to target nucleic acids without amplification, the method removes complex enzymatic reactions, nucleic acid extraction protocols, and amplification cycles, thereby simplifying the device and procedure while maintaining detection capability through optimized probe design and direct binding.

The patent replaces the enzymatic mechanical system (PCR amplification using polymerases and thermal cycling) with a direct chemical hybridization system. Instead of using enzyme-mediated amplification that requires complex equipment and multiple steps, the invention uses probe-target binding that occurs under simplified conditions, substituting the mechanical/enzymatic amplification process with a direct recognition and binding event that can be detected without complex instrumentation.

The patent applies preliminary action by pre-designing and pre-synthesizing probes with optimized sequences and structures that are ready for direct hybridization. The probes are prepared in advance with specific properties (length, composition, modifications) that enable them to bind directly to target nucleic acids without requiring amplification. This preliminary preparation of detection reagents eliminates the need for time-consuming amplification steps during the actual detection process.

The patent skips the amplification steps entirely by using direct probe-target hybridization. Instead of rushing through multiple amplification cycles, denaturation steps, and enzymatic reactions, the method jumps directly to the detection step where probes bind to target sequences in a single binding event, significantly reducing the time required from sample to result while maintaining sensitivity through optimized probe design.

The patent employs cheap, disposable probe molecules that can be synthesized at low cost using standard oligonucleotide synthesis methods. Instead of using expensive enzymes, buffers, and reagents required for PCR amplification, the invention uses stable, synthetic probe sequences that can be produced economically and used in a single detection reaction. The probes are designed to be sufficiently stable for the detection event but do not require the costly infrastructure of enzymatic amplification systems.

The patent changes the fundamental parameters of the detection system by eliminating enzymatic components and using direct hybridization. This parameter change from enzyme-mediated amplification to probe-based direct detection fundamentally alters the cost structure, removing the need for expensive thermostated equipment, enzymatic reagents, and complex buffer systems, thereby reducing both equipment and consumable costs while maintaining detection sensitivity through optimized probe design.